blastic plasmacytoid dendritic cell neoplasm (Cancer)
Information
- Disease name
- blastic plasmacytoid dendritic cell neoplasm
- Disease ID
- DOID:0081076
- Description
- "An acute leukemia that is derived from the precursors of plasmacytoid dendritic cells, with a high frequency of cutaneous and bone marrow involvement and leukemic dissemination. Skin lesions appearing on the arms, legs, face and neck are the most common BPDCN symptom. Other symptoms include low counts of healthy blood cells and swollen lymph nodes." [url:https\://pubmed.ncbi.nlm.nih.gov/30350260/, url:https\://pubmed.ncbi.nlm.nih.gov/31972688/, url:https\://www.lls.org/leukemia/blastic-plasmacytoid-dendritic-cell-neoplasm]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03485547 | Active, not recruiting | Phase 1 | Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | August 23, 2018 | January 19, 2025 |
| NCT02159495 | Active, not recruiting | Phase 1 | Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm | December 15, 2015 | December 15, 2024 |
| NCT02220985 | Active, not recruiting | Phase 2 | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors in Preventing GVHD | February 3, 2015 | April 1, 2025 |
| NCT03386513 | Active, not recruiting | Phase 1/Phase 2 | Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN | January 2, 2018 | December 2025 |
| NCT03404193 | Active, not recruiting | Phase 2 | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome | January 18, 2018 | December 31, 2024 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT02730312 | Completed | Phase 1 | PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies | August 2016 | September 2021 |
| NCT02859623 | Completed | Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN) | January 2014 | ||
| NCT00014235 | Completed | N/A | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | December 2000 | |
| NCT00397579 | Completed | Phase 1/Phase 2 | DT388IL3 Fusion Protein in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes | May 2013 | July 27, 2017 |
| NCT03974971 | Completed | Blastic Plasmacytoid Dendritic Cell Neoplasm in Korean Population. | April 30, 2019 | February 29, 2020 | |
| NCT01231919 | Completed | Phase 1 | MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia | January 2011 | |
| NCT04317781 | Completed | Phase 2 | Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant | March 27, 2020 | July 11, 2023 |
| NCT06013423 | Recruiting | Phase 2 | Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases | July 6, 2024 | October 31, 2025 |
| NCT03113643 | Recruiting | Phase 1 | SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | June 26, 2017 | May 31, 2026 |
| NCT03246906 | Recruiting | Phase 2 | Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation | September 11, 2017 | October 11, 2026 |
| NCT03779854 | Recruiting | Phase 2 | Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant | August 29, 2019 | December 31, 2025 |
| NCT04216524 | Recruiting | Phase 2 | Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm | May 29, 2020 | December 31, 2026 |
| NCT05362773 | Recruiting | Phase 1 | A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies | July 13, 2022 | March 2025 |
| NCT03075553 | Terminated | Phase 2 | Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | May 17, 2017 | May 29, 2019 |
- Disase is a (Disease Ontology)
- DOID:12603
- Cross Reference ID (Disease Ontology)
- NCI:C7203
- Exact Synonym (Disease Ontology)
- Agranular CD4+ CD56+ Hematodermic Neoplasm/Tumor
- Exact Synonym (Disease Ontology)
- Agranular CD4+ Natural Killer Cell Leukemia
- Exact Synonym (Disease Ontology)
- Blastic Natural Killer Leukemia/Lymphoma
- Exact Synonym (Disease Ontology)
- Blastic NK-Cell Lymphoma
- Exact Synonym (Disease Ontology)
- CD4+/CD56+ Hematodermic Neoplasm
- Exact Synonym (Disease Ontology)
- natural killer (NK) cell leukemia/lymphoma